Expertise
Single Entry Point (SEP) for Nano-pharmaceutical Innovative Products
Customized solutions, dedicated contact person, assessment of needs, comprehensive plan. Entire supply chain from bench to bedside.
- Biotech, Pharma and Cosmetics
PHOENIX -OITB gGmbH
About
As a Single Entry Point, PHOENIX SEP offers a top-tier and consolidated network of facilities, technologies, services and expertise to bridge the path of nanopharmaceuticals to the market. The PHOENIX SEP service portfolio offers 6 categories of services, covering all the different aspects needed for the development of nanopharmaceuticals from early stage to entry into clinical trials, namely physico-chemical characterisation, in vitro characterisation, in vivo characterisation, in silico characterisation, manufacturing and innovation. Our network covers the entire supply chain from bench to bedside, for all the RDI (Research, Development and Innovation) and technology transfer aspects from characterization, testing, verification up to scale-up, GMP manufacturing and regulatory guidance as well as services around a broad range of administration routes and offer to customer solutions tailored on their needs.
Business Domain / 分野
Pharmaceuticals / 医薬品Healthcare / ヘルスケアFoods / 食品Consultant / コンサルタントOthers /その他
Business Type / 業種
R&D / 研究開発CMO, CDMO / 製造受託、開発製造受託Others / その他
Disease Area / 疾患領域
Oncology / がんNeurology & Psychiatry / 中枢神経、精神疾患Infectious diseases / 感染症Immunology / 免疫・炎症Metabolic diseases / 代謝Musculoskeletal System / 筋骨格系Cardiovascular /循環器Gastroenterology / 消化器Dermatology and sensory system / 皮膚・感覚器Rare diseases / 希少疾患Others / その他
Technologies / 技術
Pharmacological evaluation /薬効・薬理評価Drug synthesis / 医薬品合成Drug analysis /医薬品分析Drug delivery system(DDS) / ドラッグデリバリーシステム(DDS)Safety evaluation /安全性評価Pharmaceutical ingredients / 医薬品原料Biomarkers /バイオマーカーCell cultivation system and 3D-bioprinter / 細胞培養装置、３DバイオプリンターFood testing /食品検査Others / その他
Modalities / モダリティ
Small-molecule drug / 低分子医薬Peptide, Protein / ペプチド、タンパクAntibody drug / 抗体医薬Oligonucleotide drug /核酸医薬Gene therapy /遺伝子治療Cell therapy /細胞治療Vaccine /ワクチンOthers /その他
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Companies and Academia etc. (Joint research and development purpose) / 企業やアカデミア等（共同での研究、開発を目的）Major pharma etc. (Out-licensing purpose) / 大手ファーマ等（アウトライセンスを目的）Startups, BioTech etc. (In-licensing or Partnership/Collaboration purpose) / 独自の技術やシーズを持つスタートアップ、バイオテック企業等（インライセンス、共同研究などを目的）Companies and Entities (Providing your services or technology to your clients) / 技術・サービス（研究、開発、製造等の提供を目的）CROs, CMOs, CDMOs, etc. (Partnerships)/CRO、CMO、CDMO等（インライセンス、共同研究などを目的）Others
Researched disease area / マッチングご希望の疾患領域
Oncology / がんNeurology & Psychiatryy / 中枢神経、精神疾患Infectious diseases / 感染症Immunology / 免疫・炎症Metabolic diseases / 代謝Musculoskeletal System / 筋骨格系Cardiovascular/ 循環器Gastroenterology / 消化器Dermatology and sensory system / 皮膚・感覚器Rare diseases / 希少疾患Others /その他
Researched Modality / マッチングご希望のモダリティ
Small-molecule drug/低分子医薬Peptide, Protein / ペプチド、タンパクAntibody drug / 抗体医薬Oligonucleotide drug / 核酸医薬Gene therapy/ 遺伝子治療Cell therapy / 細胞治療Vaccine / ワクチンOthers / その他
Researched Technologies / マッチングご希望の技術
Biomarkers / バイオマーカーCell cultivation system and 3D-bioprinter/ 細胞培養装置、３DプリンターFood testing / 食品検査Others /その他
Resources
Marketplace (9)
Service
Service portfolio offers 7 service categories for nano-pharmaceutical development, from early stage to entry into clinical trials.
Service
GMP-certified aseptic Fill and Finishing services including Lyophilization
- Development
- Manufacturing
- Biotech and Lifescience
Service
PHOENIX SEP: Your Single Entry Point for Nanopharmaceutical Development
Consolidated network of facilities, technologies, services and expertise to facilitate the path from bench to bedside.
- Others
- Medtech
- Consulting
- Development
- Manufacturing
- Microtechnology
- Biotech and Lifescience
Service
Physico-chemical characterisation
Techniques to characterise nanoparticles, small and large molecules, conjugates (i.e., nanoparticles loaded with drug or API)
Service
in vivo characterisation of the nanomedicine
pre-clinical in vivo characterisation of the nanomedicine under study and evaluate its safety
Service
in silico characterisation of nanopharmaceuticals
in silico characterisation of nanopharmaceuticals. Computational tools to enhance the understanding of pharmaceutical manufacturing process
Service
CMC for scale-up until industrial manufacturing of a nanopharmaceutical
CMC services for scale-up until industrial manufacturing of a nanopharmaceutical